期刊文献+

大蒜提取物S-烯丙基半胱氨酸对人食管鳞癌TE-13细胞株增殖和凋亡作用的研究 被引量:1

Effect of Garlic Derivative S-allylcysteine(SAC) on Proliferation and Apoptosis of Esophageal Squamous Cell Carcinoma TE-13 Cell Line
原文传递
导出
摘要 [目的]研究S-烯丙基半胱氨酸(SAC)对人食管鳞癌细胞株TE-13增殖、凋亡等生物学特性的影响。[方法]MTT比色法和细胞克隆形成实验检测SAC作用于人食管鳞癌细胞株TE-13的增殖活性,流式细胞术分析肿瘤细胞的凋亡,Western Blot检测细胞内STAT3、Mcl-1、Survivin蛋白的表达。[结果]SAC明显抑制TE-13细胞的增殖率和克隆形成率,并且具有时间和浓度依赖性。进一步研究发现SAC作用于细胞后通过抑制STAT3、Mcl-1和Survivin蛋白的表达,活化Active-caspase 3蛋白的表达从而诱导细胞凋亡和坏死。[结论]S-烯丙基半胱氨酸通过抑制STAT3、Mcl-1和Survivin的表达,进而抑制TE-13细胞的增殖,诱导其凋亡。 [Purpose] To investigate the effect of S-allylcysteine (SAC) on proliferation and apoptosis of human esophageal squamous cell carcinoma TE-13 cell line. [ Methods ] Cell prolifera- tion was detected by MTF and colony-forming assays. Cell apoptosis was detected by Annexin V/PI staining with flow cytometry. The expression of STAT3,Mcl-1 and Survivin was detected by Western Blot assay. [Results] The proliferation rate and colony-forming abilities of TE-13 cells were suppressed by SAC in dose-dependent and time-dependent manners. Moreover, SAC significantly induced apoptosis and necrosis of TE-13 cells through suppressing STAT3,Mcl-1, Survivin as well as activating caspase 3. [Conclusion] SAC inhibits cell proliferation and in- duces apoptosis by inhibiting STAT3 signal transduction in human esophageal squamous cell carcinomas TE-13 cell line.
出处 《肿瘤学杂志》 CAS 2014年第4期294-299,共6页 Journal of Chinese Oncology
关键词 食管肿瘤 S-烯丙基半胱氨酸 大蒜 抗肿瘤药物 STAT3 增殖 凋亡 esophageal neoplasms S-allylcysteine garlic antitumor drug STAT3 prolifera- tion apoptosis
  • 相关文献

参考文献3

二级参考文献26

  • 1刘俊茹,王原,左连富,李凤林,王莹,刘嘉琳.COX-2、p-Stat3及p-Stat5在食管癌组织中的表达及其意义[J].癌症,2007,26(5):458-462. 被引量:26
  • 2Herskovic A,Martz K,al-Sarraf M,et al.Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.N Engl J Med,1992,326:1593-1598.
  • 3Cooper JS,Guo MD,Herskovic A,et al.Chemoradiotherapy of locally advanced esophageal cancer:long term follow-up of a prospective randomized trial (RTOG 85-01).JAMA,1999,281:1623-1627.
  • 4Kelsey CR,Chino JP,Willett CG,et al.Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer.Int J Radiat Oncol Biol Phys,2007,69:770-776.
  • 5Sun Q,Liu C,Zhong H,et al.Multi-center phase Ⅱ trial of weekly paclitaxel plus cisplatin combination chemotherapy in patients with advanced gastric and gastro-esophageal cancer.Jpn J Clin Oncol,2009,39:237-243.
  • 6Minsky BD,Pajak TF,Ginsberg RJ,et al.INT 0123 (Radiation Therapy Oncology Group 94-05) phase Ⅲ trial of combined modality therapy for esophageal cancer:high-dose versus standard dose radiation therapy.J Clin Oncol,2002,20:1167-1174.
  • 7Suntharalingam M,Moughan J,Coia LR,et al.Outcome results of the 1996-1999 patterns of care survey of the national practice for patients receiving radiation therapy for carcinoma of the esophagus.J Clin Oncol,2005,23:2325-2331.
  • 8Bowman T. Garcia R, Turkson J, et al. STATs in oncogenesis. Oncogene, 2000, 19:2474-2488.
  • 9Mora LB, Buettner R, Seigue J, et al. Constitutive activation of Stat3 in human prostate lumors and cell lines: direct inhibition of Slat3 signaling induces apoptosis of prostate cancer cells. Cancer Res, 2002, 62:6659-6666.
  • 10Song Jl, Grandis JR. STAT signaling in head and neck cancer. Oncngene, 2000, 19:2489-2495.

共引文献24

同被引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部